Figure 1 from Modulating Treatment Outcomes of Patients with Solid Tumors in Immunotherapy Trials: A Drug Interaction Analysis from a Phase I Unit

Key Points

• Antihistamine use may influence treatment outcomes in patients with solid tumors undergoing immunotherapy trials.
• The analysis highlights a potential association between antihistamine use and tumor responses, offering insights for improved therapies.
• This phase I unit analysis leverages drug interaction methodologies to assess the impact on tumor responses in immunotherapy.
• Understanding these interactions may enhance treatment strategies, particularly in solid tumor immunotherapy contexts.